Studies of a novel photosensitizer palladium-bacteriopheophorbide (Tookad) for the treatment of prostate cancer

Zheng Huang; Qun Chen; Pierre-Herve Brun; Brian C. Wilson; Avigdor Scherz; Yoram Salomon; David L. Luck; Jill Beckers; Fred W. Hetzel

doi:10.1117/12.474097

13 June 2003 Studies of a novel photosensitizer palladium-bacteriopheophorbide (Tookad) for the treatment of prostate cancer

Zheng Huang, Qun Chen, Pierre-Herve Brun, Brian C. Wilson, Avigdor Scherz, Yoram Salomon, David L. Luck, Jill Beckers, Fred W. Hetzel

Author Affiliations +

Proceedings Volume 4952, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XII; (2003) https://doi.org/10.1117/12.474097
Event: Biomedical Optics, 2003, San Jose, CA, United States

Abstract

In this study, photodynamic therapy (PDT) mediated with a novel, second generation photosensitizer Tookad (palladium-bacteriopheophorbide, WST09, STEBA Biotech, France), is investigated as an alternative modality in the treatment of prostate cancer. In vivo normal canine prostate and spontaneous advanced prostate cancer are used as the animal model. PDT was performed by irradiating the surgically exposed prostates with a diode laser (763 nm, 150 mW/cm) to activate the i.v. infused photosensitizer. The effects of drug concentration, drug-light interval, and light fluence rate on the PDT efficacy were studied. The prostates and adjacent tissues (bladder and underlying colon) were harvested and subjected to histopathological examination. During the one-week to 3-month period post PDT treatment, the dogs recovered well with little or no urethral complications. Prostatic urethra and prostate adjacent tissues (bladder and underlying colon) were well preserved. Light irradiation delivered during drug infusion or within 15 min post drug infusion induced the similar extend of damages. PDT induced prostate lesions in both normal and cancerous prostate were characterized by marked hemorrhagic necrosis and atrophy. Maximum lesion size of over 3 cm in dimension could be achieved with a single 1-cm interstitial treatment, suggesting the therapy is very effective in ablating cancerous prostatic tissue. In conclusion, the second generation photosensitizer Tookad mediated PDT may provide an effective alternative to treat prostate cancer.

Citation Download Citation

Zheng Huang, Qun Chen, Pierre-Herve Brun, Brian C. Wilson, Avigdor Scherz, Yoram Salomon, David L. Luck, Jill Beckers, and Fred W. Hetzel "Studies of a novel photosensitizer palladium-bacteriopheophorbide (Tookad) for the treatment of prostate cancer", Proc. SPIE 4952, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XII, (13 June 2003); https://doi.org/10.1117/12.474097

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available